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ABSTRACT 
Gauging community responses to the WHO 2015 recommendation to provide antiretroviral 
treatment (ART) to all people living with HIV (PLHIV) is critical.  There is limited qualitative 
evidence on the acceptability of this ‘Universal Test and Treat’ (UTT) strategy or community 
understanding of the impact of ART on reducing HIV transmission, promoted as ‘Treatment as 
Prevention’ (TasP).  This paper explores early understanding of UTT and TasP, in 21 urban 
communities in South Africa and Zambia in 2013, prior to a community randomized trial of 
combination prevention - HPTN 071 (PopART). It draws on participatory research conducted in 
each community which carried out group discussions and interviews with 1202 respondents and 
203 structured observations. Participants were largely unfamiliar with the concepts of UTT and 
TasP.  They were concerned about an accompanying de-emphasis on sexual behaviour change.  
Treatment and prevention seemed, at first glance, to be experienced separately. With the 
exception of the prevention of mother-to-child transmission (PMTCT), ‘prevention’ seldom 
came into discussions about ART. This was partly because this science had not yet been 
explained to many and also because it was not an easy ‘fit’. Contemplating the link between 
treatment and prevention, participants emphasised both PLWH ‘taking care’ of themselves 
through good health and preventing disease progression and the moral responsibility of PLHIV 
to prevent HIV transmission.  To avoid igniting moralizing and blaming when introducing UTT 
and TasP, we should capitalize on the ‘taking care of yourself’ legacy whilst boosting public 
responsibility through broad anti-stigma education and patient empowerment efforts.  
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Introduction 
Thirty years into the epidemic, HIV is an integrated dimension of daily life in South Africa and 
Zambia.  Over this time, communities have had an astonishing exposure to care, pain, suffering, 
death and change (1)  Since the widespread implementation of treatment in southern Africa from 
2006, HIV programming has increasingly moved toward ‘universal’ uptake of testing and 
treatment. This transition has been galvanized by growing evidence of the advantages of earlier 
treatment initiation both for People Living with HIV (PLHIV) and to prevent HIV transmission 
(2).  The emphasis on reducing HIV transmission increasingly falls under a concept labelled 
‘Treatment as Prevention’ (TasP). This has become a driving ideology for HIV policy (3-5), 
influencing funding, focus and programmes and aligning treatment closer to prevention.  The 
recent WHO guidelines recommend ART initiation regardless of immune capability (i.e. CD4 
count).  In the context of the anticipated scale-up of ART access, it is important to understand 
how people living in areas of high HIV prevalence understand the concepts of TasP and 
Universal Test and Treat (UTT).  In Africa, there is a lack of community-based research on the 
acceptability of TasP, UTT and other ARV prevention technologies (e.g. Pre-Exposure 
Prophylaxis), particularly about the concerns of implementers and users (6-9).  As Young and 
McDaid (8)  observe, ‘Questions about acceptability [of TasP]…need to be push beyond simple 
willingness, to understand the context within which interventions…might be acceptable and/or 
preferred’ (p.212).  In this paper we use a ‘social public health’ approach (10) to describe the 
influence of social and historical context on understandings of TasP and UTT in places where 
access to ART regardless of CD4 count is being introduced, implemented and used in the HPTN 
071 (PopART) trial. The emerging analysis identifies ‘good health’ and ‘moral authority’ as two 
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underlying concepts that could shape the uptake of these strategies, with clear implications for 
acceptability and HIV-related stigma.  
 
Late in 2012, 21 urban areas across Zambia and the Western Cape, South Africa were selected as 
‘communities’ for a cluster-randomised trial ‘Population Effects of Antiretroviral Therapy to 
Reduce HIV Transmission’ (HPTN 071 (PopART)) (11).  This trial measures the impact of a 
combination prevention package on HIV incidence at population level. The intervention (2014-
17) encourages all residents to test for HIV.  Those living with HIV are linked to HIV services 
located in government health facilities.  Condoms, voluntary medical male circumcision 
(VMMC) for HIV-negative men and treatment of sexually transmitted infections are promoted 
(ibid).  In seven of the 21 communities, immediate ART was initially provided for PLHIV 
irrespective of CD4 count; in the other 14 communities, PLHIV were offered ART according to 
national treatment guidelines which, in 2013, stipulated starting ART when the CD4 count 
dropped below 350.  Due to the revised WHO treatment guidelines (2015), from June 2016 
onwards, early ART was made available and promoted in all Zambian HPTN 071 (PopART) 
trial communities.  South Africa is likely to follow suit in 2017. This paper draws on rapid 
qualitative research carried out prior to the HPTN 071 (PopART) intervention implementation. 
The aim of this paper is to explore how HIV treatment and prevention is understood by local 
residents across the communities, and to consider the implications for the recent expansion of 
early access to ART.   
 
Methods 
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Qualitative research was carried out in each of the 21 communities in December 2012 to May 
2013 before the randomisation of each community to different intervention packages.  Each 
community is defined as the catchment area of a government health facility where HIV services 
and ART are available.  
 
Over a period of 12 days in each community, a mix of exploratory, qualitative methods were 
used. These included observations of key places, spaces and boundaries of relevance to local 
context and HIV and interviews with groups and individuals (see Tables i and ii).    Drawing on 
an approach used in three other community randomised trials to rapidly collect data on local 
context, the methodology aims to allow comparison between different communities by collecting 
data systematically across a predefined set of four descriptive dimensions (12-15).  The 
participatory techniques applied include drawings and statements on cards, mapping, character 
cards, HIV concept mapping and pile-sorting, free-listing and timelines (16).  The research is 
carried out in a sequence that starts with broader observations and narrows down to the more 
focused discussions, observations and interviews.  
 
The data were collected by graduate social scientists assisted by local resident fieldworkers (in 
Zambia) and research assistants (in South Africa), with one social scientist and one research 
assistant/fieldworker carrying out the research in each community.  The method was piloted in 
one community in each country, after which the approach and tools were adjusted.  
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Key themes explored included places considered relevant to the HIV epidemic, the influence of 
wealth, poverty and risk taking on HIV, reflections on the history of HIV and ART, 
understanding and ranking of HIV prevention strategies and listing and ranking of local HIV 
stakeholders. The HPTN 071 (PopART) trial specific interventions were also explored; namely 
views on Voluntary Medical Male Circumcision (VMMC), household-based counselling and 
testing, early initiation of ART, links between treatment and prevention and the feasibility of the 
proposed universal test and treat intervention.   
 
All 1202 (745 women, 457 men ) participants in either interviews or discussions (see Table i) 
were adults (aged 18 and over) currently living or working in the communities.  Group 
discussion participants of different gender and age (older men, younger men, older women, 
younger women) were selected from different locations in the community.  In South Africa, this 
proved more challenging due to security concerns and ethnic divisions.  Subsequently group 
discussions in South Africa were often smaller and conducted with more spontaneous groups of 
people, for example, young men who had gathered near a playing field to watch sport.  Pre-
arranged group discussions were also held with residents who had particular expertise and 
perspective on HIV recruited through the local health facility, non-governmental organisations 
(NGOs) and because they were located and identifiable in the community.  These included health 
committee members, members of NGOs, church leaders, health care workers (including 
community lay volunteers), traditional healers and PLHIV.  Key informants included health 
facility staff, private clinicians, church pastors, traditional healers, government representatives, 
civil society representatives (from non-governmental/faith based/community based 
organisations), a sex worker and PLHIV. If possible, discussions and interviews were held away 
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from the health facility to encourage participants to talk more freely about health services quality 
and more broadly about HIV management.  The 203 observations were carried out in places of 
relevance to HIV and local context (see Table ii). 
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Table i: Group discussions and Key Informant Interviews 
Activity Zambia South Africa Zambia South Africa 
Groups* Groups
* Participants* Participants* 
Group 
Discussions 
(GD) and 
Key 
Informant 
Interviews 
(KII) 
NHC/Comm. reps.    12 4 153 26 
HIV Specialists 10 8 104 49 
Older Women 12 6 129 29 
Younger Women 12 8 136 30 
Older Men 10 6 80 14 
Younger Men 12 8 127 29 
Gender mixed 
groups 
1 3 5 25 
PLHIV 12 5 141 30 
Key Informant 
Interviews 
-  -  65 30 
Total GDs: 81 48 940  
(567 women) 
262  
(177 women) 
 
* Neighbourhood Health Committee = NHC; Comm.reps = Community Representatives; HIV Specialists includes PLHIV and professsional, lay 
and alternative health providers 
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Table ii: Structured Observations 
Activity Zambia South Africa Total 
Activity* Activity* Total* 
Observations Transport depot 24 18 42 
Transect Spiral Walk 12 9 21 
Healthcare facility observation 29 10 39 
Market Areas 12 8 20 
Hair Salons/Barbers 12 9 21 
Drinking Places & Night 
observation 
24 8 32 
Church 12 0 12 
Guest House Observations 11 0 11 
Additional Observations 4 1 5 
Total Observations: 140 63 203 
 
* Health facility observations includes antenatal care clinics, ART clinics and VMMC. 
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The key topics of HIV treatment and prevention presented in this paper were explored both 
through participatory activities and direct questions.  Participants were encouraged to focus on 
relating responses to ‘their community’.  Understanding and ranking of HIV prevention 
strategies was explored initally in group discussions with HIV specialists and then in other 
community groups.  Concept mapping (17) was used to generate statements, key options, themes 
and ranking around a key question - ‘What is HIV prevention in this community?’   
 
Outputs were written up through routine debriefing of researchers during fieldwork and an 
analysis workshop carried out immediately after data collection.  All recordings were then 
transcribed and translated verbatim for finer analysis.  ATLAS.ti was used to manage the data 
based on a coding frame with the broad codes of ‘HIV prevention’ and ‘Living with HIV’ 
(including treatment generally and ART specifically) and HIV-related stigma sub-codes of both.  
This paper draws on the finer analysis process.  
 
Ethical approval 
Ethical approval was obtained for this research from the University of Zambia Humanities and 
Social Sciences Research Ethics Committee, the London School of Hygiene and Tropical 
Medicine Research Ethics Committee and the University of Stellenbosch Health Research Ethics 
Committee.  Governmental health authority clearance was also obtained in South Africa and 
Zambia.  Written informed consent was obtained from all research participants engaged in 
research activities other than observations.  Outputs and coded data removed community, place, 
job title and person names.  A key ethical issue encountered was lack of safety in the field – 
particularly in South Africa at nights and weekends and around the time of the monthly welfare 
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grants pay out (18).  Precautions taken included researchers working in mixed gender pairs, 
matching researcher ethnicity to the predominant ethnicity and language of any one community, 
working closely with governmental and local authorities, referral to appropriate services and 
withdrawal from the field or activities in the face of heightened threats (ibid).  
 
The Communities 
The population size of the 21 communities is estimated to range from 14,500 to 161,615 with 
Zambian communities having larger populations.  The communities were selected partly on the 
basis of relatively high HIV prevalence, for which pre-HPTN 071 (PopART) trial estimates 
ranged between 12 and 23% (11).  Common features are population expansion and mobility 
(both daily and transient) and a majority of the population categorised as ‘urban poor’.  Key 
infrastructure includes at least one government health facility within walking distance for most 
residents.  Housing is a mix of densely situated formal and informal housing, often with poor 
waste disposal.  High unemployment, migrant or seasonal work and a bustling informal economy 
are other common features.  More distinctive features include race segregation in South Africa, 
proximity to international borders in six Zambian communities and the lack of a welfare state in 
Zambia.  Asked ‘what kind of place is this?’ participants initially identified poverty, crime and 
substance abuse (both alcohol and particularly in South Africa, recreational drug use).  All three 
were linked to transactional and casual sex and teenage pregnancies and, thereby, the risk of 
HIV.   
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It is in the context of these key physical features and harsh realities – and equipped by social 
networks, recognition of community action and existing infrastructure and response – that HIV is 
navigated by residents.  HIV compounds an already long list of everyday challenges for residents 
and is not always a foremost priority (19, 20).  Analogous to residents of a favela in Brazil, they 
are sometimes ‘impotent’ in the face of ‘ubiquitous’ realities (21).  Typically, participants 
described these challenges as omnipresent and inescapable.  As one Zambian NGO employee 
described “[we are] victims in our catchment area”.  One older male Zambian participant starkly 
states: “Hunger greets you each time you enter some of these homes, we wake up and sleep with 
poverty”.  Similarly a young woman South African participant said: “there’s not a person, not a 
guy that stays in the place that doesn’t take tik [low-grade methamphetamine often mixed with 
other substances] … You can’t even walk safely in this place anymore because you are scared 
something will happen to you”.  
 
‘TasP’ – as a concept  
In 2013, there was mostly no spontaneous use of or familiarity with the terms ‘UTT’, ‘TasP’ or 
‘Test and Treat’, although participants were familiar with other HIV acronyms.  For example, a 
group of Zambian PLHIV asked “UTT? What kind of animal is that?” Only one Zambian health 
care worker carefully broke it down and described it in her own words, “Universal means 
something that is broad and all over – testing and treatment is something that is on the large 
scale”.  Qualitative research in Scotland (9) revealed the same limited awareness of ‘TasP’ as a 
‘branded’ term.  Resistance to the term was expressed by national policy makers and study 
implementers in Swaziland, partly on the basis of clarity and considering that they were already 
moving towards offering this as the best standard of care (7).  Both ‘TasP’ and ‘UTT’ have been 
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introduced and advocated under an acronym umbrella, similar to many trends in global HIV 
policy.  Drawing on longitudinal interviews with PLHIV in the UK and South Africa, Squire 
describes how ‘clouds of…acronyms’ were ‘suffusing’ interviews, an emblem of ‘the acronymic 
optimism about treating away the pandemic expressed by many medical and policy 
organisations’ (22).   
 
Participants were asked ‘Have you heard of ARVs being used to prevent HIV?’.  In both 
countries the first response to this question from participants (including health care workers and 
PLHIV) was usually bemusement, and sometimes even laughter.  They often stated they ‘hadn’t 
heard of it’ and were hearing of it for the first time ‘today’.   Linking treatment to prevention was 
initially counter-intuitive; if you were living with HIV then prevention seems less relevant.  If 
you were HIV-negative then treatment seemed less relevant.  A South African key informant 
stated, “no ... if I am HIV negative then I take ARVs, it’s not going to assist me”.  Bemusement 
was quickly followed by discussions, more commonly on the efficacy of ART, testing initiatives, 
early initiation of ART, Prevention of Mother-To-Child Transmission (PMTCT), HIV 
transmission during sex and birth, the prevention of illness in PLHIV and the role of PLHIV in 
preventing transmission.  A few participants also spontaneously discussed Post-Exposure 
Prophylactics (PEP), the use of ‘Truvada’ and the impact of ARVs on the HIV virus.  Overall it 
was mostly PLHIV and HIV specialists (see earlier definition of the latter) who had more 
detailed information about HIV transmission and the ‘science’ behind ARVs, with a few 
exceptions (for example, older men in one Zambian site).  However, most participants were 
familiar with CD4, viral load, sexual transmission, reducing transmission to children and 
adherence to ART.  Many discussions also contained curiosity, caution and confusion about the 
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concept, and the importance of PLHIV maintaining health by sticking to particular instructions 
and moral codes.    
 
In relation to other acronyms linking treatment and prevention, all participants were familiar with 
‘PMTCT’. Some HIV specialist participants mentioned ‘Prevention with Positives’, one of 
which referred to ‘PWP’ defined as follows “PWP - Prevention With the Positive - prevention 
should start with those who are positive, not to infect others who are HIV negative”.  PEP (a 
drug regimen taken for a month after an exposure to HIV to reduce the chances of infection and 
available in health facilities) was familiar to a limited proportion of health care workers and 
PLHIV.  It was associated with health care workers being exposed to blood, to rape cases and to 
unprotected sex.  A few Zambian HIV specialist participants identified ‘Truvada’ being used for 
‘prevention’, ‘to help people not catch HIV’ and for PEP.  For others ‘Truvada’ was something 
they heard about ‘on the radio’ or the internet for ‘use outside Zambia’.  One health care worker 
in Zambia, for example, said that ‘Truvada’ was not available at the health facility but people 
were discovering it could be used for prevention through the internet, commenting “hence some 
promiscuous persons would want to take the medication before sleeping around with different 
partners”.   
 
Pregnant women living with HIV have been encouraged to take ART since 2002 in both Zambia 
and South Africa.  Zambian participants quickly related the concept of ART as prevention to 
PMTCT.  PMTCT was acknowledged to have reduced infant mortality and was strongly 
advocated with the onus put on a woman to ‘know her status’ and to come to antenatal care 
(ANC) with her partner. Treatment adherence during pregnancy was considered critical.  This is 
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captured in a Zambian HIV specialist’s comment, “they give birth to a baby you find the baby is 
negative because if adherence is 100% but they are those we see that the mother is HIV positive 
and the baby is born from the womb with HIV then no adherence”.  In South Africa, while the 
PMTCT programme has been highly effective, there was some scepticism about the long-term 
impact of PMTCT.  Some participants relegated PMTCT to a ‘secondary prevention strategy’ 
because, in their view, it had not prevented the mother getting infected.   
 
Treatment and Prevention as Distinct Categories 
Unprompted, treatment and prevention were more often considered as requiring distinct 
management by participants in both Zambia and South Africa.  This is reflected in memories of 
the history of HIV, discussed using a timeline with participants, and a perceived division of 
responsibility for treatment and prevention services. Five broad chronological phases were 
identified in both countries with more detail recalled in Zambia. Treatment (including 
unavailability of treatment) dominated the first four phases and prevention the fifth, reflecting 
how the global prevention emphasis has trickled down.  The 1980s were recalled as a period 
when the first cases of HIV were reported.  In the 1990s, treatment was unavailable, health 
education was limited and there was little motivation to test for HIV.  Vivid memories of family 
members and friends being frail and bedridden, of death and of stigma were recalled for this first 
period.  Zambian participants also recollected Home Based Care Organisations (HBC) providing 
practical and spiritual support.  The late 1990s to 2005 were marked by awareness of HIV 
treatment being available to countries and people with more resources but unavailable to 
everyone else.  This changed from 2005 onwards when ART was available and free.  This free 
provision was regarded as ‘progressive’ and initial fears about the impact on fertility and the 
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strength of the drugs ebbed.  However, residual concerns about sustainability, stigma associated 
with accessing treatment and the commitment to life-long treatment remained.  The final phase 
focused, for the first time, on prevention – particularly VMMC.  The possibility of a cure for 
HIV was also mentioned, with the expectation that akin to ART, a cure would be first only 
available to those in ‘the West’.  It was also evident that in both countries, HIV services were 
usually associated with either treatment or prevention. The government health facility and key 
supporting NGOs were associated more with treatment and certain other NGOs associated more 
with particular HIV prevention initiatives (for example, couple counselling, mobile HIV testing, 
‘door to door’ HIV testing and VMMC).   
 
Acceptance of Universal Testing and Treatment 
Participants were supportive of everyone testing and knowing their status.  Some participants 
(but not all) linked testing everyone to treatment.  As one South African health care worker 
reflected, “we are moving too slowly... if we could test more people …then we can …get more 
people on treatment”.  Only a few participants linked ‘testing everyone’ to treatment ‘regardless 
of CD4 count’.  One Zambian health committee were confused by putting PLHIV on treatment 
irrespective of CD4 because they understood that PLHIV with high CD4 were already less likely 
to transmit HIV because they had less ‘kadoyo’ (meaning ‘insect’, as often used in Zambia to 
refer to the HIV virus).  One Zambian PLHIV recalled hearing on the radio that ARVs will be 
given to PLHIV who did not know their status “to reduce the chances of those that are positive 
but have never been tested from transmitting the virus to other people”.  Asked more specifically 
about early treatment for PLHIV, many participants said that in their experience starting ART 
‘early’ rather than late was beneficial.  Some then went on to imply that PLHIV who opt not to 
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go on ART are spreading the virus.  Holt identifies the same blaming tendency between treated 
and untreated homosexual men living with HIV in Australia, framing it as a sustained tendency 
to pit ‘unhealthy’ against ‘healthy’ (23).  
 
‘Taking ARVs’ and Boosting the Health of PLHIV 
In both countries, participants rarely used the term ‘ART’.  Sometimes they used the term 
‘ARVs’ or ‘RVs’ but mostly they referred to ART more obliquely, speaking of ‘the medicine’, 
‘medication’, ‘the pills’ and ‘the drugs’.  In Zambia, multiple euphemisms were often used to 
talk about ART.  These touch on the appearance, being seen taking ART, dependency on ART 
and provision of ART.  Examples include ‘beans’ (shape of the pills), ‘joining the choir’ (lining 
up for treatment), ‘kutopin’ga’ (a play on ‘topping up’ mobile phone talk-time) and 
‘government’s drugs’.  These euphemisms are considerably more pragmatic and optimistic than 
other terms still circulating in local discourse for PLHIV which are overwhelmingly derogatory, 
touching on death, physical frailty and ‘improper’ sexual behaviour.  Many of these terms 
predate the availability of ART.  For example the euphemism ‘kanayaka’ has been widely used 
since 2002 (24).  Meaning ‘the light is on’, ‘kanayaka’ indicates the moral, physical and social 
exposure of PLHIV.  This use of euphemisms in Zambia provides an indirectness which can both 
protect and obliquely expose PLHIV since they provide ‘doubts about what, exactly, they mean’ 
(22).  In South Africa, in some descriptions of ART initiation, the box of ARVs was equated 
with a casket (coffin), symbolising the end of PLHIV’s ability to live without medical 
sustenance.  
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By 2013, it is evident that ART – or ‘the medicine’ – was widely acknowledged in both countries 
as both life-saving and life-prolonging, allowing PLHIV to regain health and resume social and 
livelihood activities.  PLHIV in Zambia reflected on this, “the coming of this medication has 
brought life to us.... ARVs have done a great job!  We used to die a lot; we used to die when one 
is not supposed to die. The coming of this medication has brought life to us”.  A South African 
health worker exclaimed, “they [ARVs] pick up someone who was bedridden and get them to 
use their feet again… there is nothing better than ARVs”.  This ‘Lazarus’ effect and deep 
appreciation of ART has been widely documented in Sub-Saharan Africa (25, 26).   
 
Aside from ART, across all communities, other forms of medicine and healing were also used 
for managing HIV by some PLHIV.  The alternative approaches are used with the aim of 
boosting immune systems and spiritual life as well as to help manage side-effects.  These 
alternatives, revolving around ‘faith healing’ and herbal remedies, focused more on health, 
symptom treatment and cure than prevention.  However, the moral principles of religious faith 
linked treatment and prevention.  ‘Faith’ was regarded as a form of protection from HIV because 
church goers were supposed to have certain moral behaviours (for example, fidelity) which lower 
HIV risk.  An older Zambian woman professes this logic, “follow God’s teachings and all those 
that are following these teachings are protected from HIV”.  Faith healing, linked to Pentecostal 
church movements (27) and especially in Zambia, was also sometimes claimed to cure HIV 
through healing sessions (often all night) with prayers and cleansing rituals using water, anointed 
oil, milk, salt and stones.  Some pastors were said to recommend ‘throwing away’ ARVs. 
Traditional healers also sometimes claimed to have a cure for HIV but were less likely to instruct 
PLHIV to stop taking ARVs and more likely to refer to health services.  Herbal remedies, 
18 
 
sometimes referred to as ‘immune boosters’ and a mix of local herbs and substances from 
outside the countries, were marketed and used in all communities.  In South Africa these 
included magogotha (herb), ‘Eastern Cape’ foods (traditional herbs), seafood tablets, African 
potato, herbal detox to cleanse the blood and marijuana.     
 
‘Taking ARVs’ was accompanied by specific instructions pertaining to alcohol use and diet. 
Health care workers in both countries also put emphasis on ‘good nutrition’ and ‘taking 
medicine’.  This pressure to take food with ART resounds with hunger being an experienced 
side-effect of ART (28).  One South African PLHIV explained “when you take the pills on an 
empty stomach, they make you sick and kill us”.  The poignancy of this ‘hunger’ in the context 
of poverty is more acute in Zambia where there is no disability grant or nutrition schemes like 
those found in South Africa.  
 
Confusing ‘Treatment as Prevention’ with prevention of disease progression 
Other than PMTCT, most community participants were not familiar with ART reducing onward 
transmission of HIV.  Participants were familiar with ART reducing ‘the virus’ (viral 
suppression) and some deduced the possibility of ART reducing transmission.  Most participants 
would infer that ‘treatment as prevention’ meant prevention of disease progression among 
PLHIV.    
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Viral suppression as a result of taking ART was familiar to participants.  ARVs were understood 
by some participants to reduce the replication of the virus if there was ‘good’ adherence.  This 
was sometimes described as ARVs ‘suppressing’ HIV.  A few participants extended this to 
observations on the implications for HIV transmission.  This is reflected in the contemplations of 
an older Zambian man, “I know that when a person starts taking ARVs and his immune system is 
weak and the viral load had really dropped, when that person starts taking ARVs his viral load is 
boosted and the strength of the virus is reduced and the chance of that person passing the virus is 
reduced… so I would say to an extent the ARVs also help to prevent the spread of HIV”.   
 
The notion of undetectable viral load could be perplexing.  Older South African women 
pondered; “They say sometimes when you take your pills right the virus becomes undetectable in 
the body, what causes that? People say there is no virus anymore and they want to stop taking the 
pills”.  Indeed, ARVs were not believed to cure HIV. For a few participants, the fact that ARVs 
did not cure HIV was a link with prevention.  For example, one South African health care worker 
retorted “because it [ART] doesn’t cure the HIV it is prevention”.   
 
HIV specialists were usually the participants most familiar with bio-medical explanations of 
ART reducing HIV transmission.  HIV specialist Zambian participants from two communities 
involved in related HIV research expounded, “it is scientifically proven like nowadays that you 
can’t, you can’t pass the virus to another person”, later qualifying “if someone is on ART they 
cannot pass the virus”.  Only in one Zambian community did any participants recall the specifics 
of this ‘science’ where a group of PLHIV recalls, “research being carried out about two years 
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ago … it was found that tenofovir reduces HIV in the body by 90% and the research was done on 
homosexuals and it was found that the drugs was 90% effective in reducing the transmission of 
HIV”.  A South African health care worker draws on an analogy of having sex with someone 
who has a ‘raw’ untreated STI; “you see if you get treated with that STI yes but I sleep with you 
that guy will not have an STI so yes I think the infection will be minimal”.  More unusually one 
older Zambian man (not a HIV specialist) noted, “ARVs is one method of prevention because 
when the viral load in the blood stream is low, chances of infecting others become low unlike 
when it is high”.  A Zambian HIV specialist mentioned that ‘D’ has been added to the ‘ABC’ 
(‘abstinence’, ‘be faithful’ and ‘condom’) campaign – “ABCD… [because] ….drugs are also 
used as HIV prevention these days’.  
 
Alongside suppressing viral replication, ARVs were recognised as ‘boosting’ the immune system 
and, thereby, the health of PLHIV.  This ‘boost’ was deemed necessary when PLHIV had a low 
CD4 count and/or were seriously ill.  ‘Re-infection’ is commonly understood as PLHIV 
preventing themselves from being infected with a different strain of HIV by abstaining from sex, 
consistently using condoms or by having sex with the same long-term partner.  Studies in Kenya 
(6) and Swaziland (7) also documented the latter concerns about re-infection amongst health 
workers and PLHIV. Zambian HIV specialists in one community said they discouraged PLHIV 
having multiple sexual partners partly because of the risk of re-infection.  They explained to 
PLHIV, “You are going to re infect each other, you are going to re infect, every day you are 
receiving or giving out…”.  
 
The Legacy of Behaviour Change and the Risk of Sexual Disinhibition  
21 
 
Underlying concerns about using ART as prevention were any contrary implications for sexual 
control and behaviour.  This is captured by an older Zambian man who argued “ARVs cannot 
prevent HIV if one is taking them but continues engaging in multiple sexual relationships”.  The 
latter emphasis echoes the legacy of the vigorous promotion of sexual behaviour change from the 
late 1980s to mid-2000 in Sub-Saharan Africa (20, 29, 30).  The well-known ‘ABC’ campaign is 
one example of this.  Many participants noted how the focus on sexual behaviour change had 
now ebbed; this was often voiced as a move away from “no sex”.  The more the ‘treatment as 
prevention’ concept was explored with participants, the more the discussions shifted to a 
perceived risk of ART driving transmission through lifting ‘risky sex’ sanctions developed 
earlier on under this behaviour change flag (29).  A South African key informant talks about 
‘girls’ who are on ARVs and who are ‘big’, saying “their attitude says that they are HIV 
negative…they don’t have the attitude of sick people who are sick…because they changed from 
very thin people…maybe people will be more careless you know what I mean”, then going on to 
express his concern that people will no longer fear getting HIV because if “you get the pills in 
time you are going to get fit and … gym”.  Zambian middle aged men make a similar claim, 
“ART contributes to the spread of HIV because most people on ART are having many sexual 
partners”.  
This concern about newer prevention technologies leading to increased sexual risk-taking has 
been coined as ‘sexual disinhibition’ (31).  For example, community concerns about VMMC 
encouraging circumcised men to have unprotected and casual sex have been documented in a 
number of Sub-Saharan African countries including Swaziland(32).  In all communities in both 
Zambia and South Africa, fears about sexual disinhibition also cropped up in relation to VMMC.   
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HIV Prevention – ‘Taking care of yourself’ 
Given that ART was generally not associated with prevention, it important to understand what 
was understood by HIV prevention.  The phrase ‘Taking care of yourself’ was frequently lined 
up with prevention in both countries.  Prevention was often recognised in both Zambia and South 
Africa as a combination of approaches, echoing the notion of ‘combination prevention’ now 
widely advocated (4).  One South African key informant elaborated, “It’s a combination of all of 
them, we can’t really single one out”.  When talking directly about HIV prevention, in Zambia, 
participants understood the concept of ‘HIV prevention’ but more commonly spoke of ‘reducing 
HIV transmission’.  Women were said to know more about HIV prevention in Zambia – but men 
were said to have the ‘upper hand’ (i.e. the control).  A South African PLHIV presented a 
considered approach to the responsibility of PLHIV in his definition of HIV prevention, “if you 
are positive to take the necessary precautions to prevent yourself from spreading the disease and 
also taking care of yourself, taking the treatment and using condoms”.  Another South African 
key informant also conveyed a combination of preventive strategies, “HIV prevention, I think 
HIV prevention is…you prevent HIV by taking care of yourself. You must condomise, ja, 
and…if you must, stick to your wife.  Stuff like…that”.   
 
Some participants pointed out how prevention was necessary because there was, as yet, no cure. 
Zambian participants listed and explored a greater number of prevention options and were 
notably more optimistic about preventing the transmission of HIV.  Some prevention options had 
a moral (often Christian) zeal, for example ‘instilling Christian values’ and ‘Christian principles’ 
were listed.  A range of Zambian discussion groups recorded ‘going to church’ as an explicit 
prevention option. This is illustrated by young women who explained, “going to church is very 
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important and at church, there are rules as well that enables a person not to commit sexual sin”. 
South African participants recalled fewer prevention options than Zambians.  They recognised 
their bio-medical effectiveness but were more cynical about their uptake, correct and consistent 
usage and long-term viability.  Fatalism around getting infected was also more dominant in 
South Africa; as one South African man expressed “If I was meant to be infected with HIV then I 
would be.  It’s like driving and you get involved in a car accident by hitting an animal that is on 
the road.  There is no avoiding an accident that was meant for you”.  
 
The consensus was that abstinence in particular was an unattainable ideal or – as participants put 
it – ‘not practiced’ despite being promoted and recommended at community level.  HIV 
specialists in one Zambian community wryly remarked “the bible says thou shall abstain but 
people do not abstain from sex”.  As one South African key informant expounds, “Abstinence, of 
course doesn’t work.  It doesn’t work for them [community members].  It works for preventing 
but it will never work for them”. ‘Be faithful’ however was considered more realistic; “for me 
HIV prevention is just to be faithful with your partner” (South African key informant).  Male 
condoms were considered one of the primary practical means of prevention, particularly for 
young men and women.  However, within steady sexual relationships they are regarded as a 
symbol of mistrust; this has been the case since they were promoted earlier on in the HIV 
epidemic (30, 33).  Condoms were also promoted amongst PLHIV by health care workers and 
PLHIV, particularly in Zambia, to prevent ‘re-infection’.  
 
Education and testing for HIV emerged as key prevention strategies with an emphasis on 
‘staying HIV-negative’.  Sometimes the latter message could overemphasise the difference 
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between being HIV-positive and HIV-negative.  For example, health specialists in one Zambian 
community listed ‘stay HIV-, stay HIV+’ as a prevention strategy.  VMMC strategies were also 
experienced as underscoring this ‘sero-divide’ (23) by reaching out to HIV-negative men and 
often excluding men  living with HIV.  Participants in most Zambian communities had detailed 
knowledge of VMMC and were often curious to learn more about it.  This was a stark contrast to 
South Africa where VMMC was always left out of listing during concept mapping, was hard to 
even talk about (and discussions about it were notably held in a low voice) and ‘was not known 
as a prevention strategy’.  VMMC was largely rejected by members of the black, Xhosa speaking 
community as medical circumcision infringed on the traditional practices of male circumcision 
and the cultural significance of entering manhood through this experience.  Participants talked 
about ‘going to the mountains’ and a strong preference for their own ‘initiation’ described by one 
South African health care worker as “going to the bush”.   
 
In at least three Zambia communities, the partial nature of the protection afforded by VMMC 
was emphasised by participants.  And, on the grounds that VMMC ‘only lessens’ the chances of 
infection and does not offer ‘complete protection’, some South African participants claimed that 
VMMC was disqualified as a prevention strategy.   
 
Overlooking social response and movements 
Structural constraints on ability to navigate prevention and treatment options require particular 
attention in Sub-Saharan Africa.  Indeed, whilst participants in both countries acknowledged the 
central role and transformative agency of ART, they discussed HIV firstly alongside other key 
challenges of the places where they lived.  These prevailing challenges – most notably poverty, 
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housing, food security, unemployment, substance abuse, crime, violence – were sometimes more 
overbearing than HIV (19).  They were also explicitly linked to the risk of acquiring HIV by 
participants through patterns of transactional sex and risky sexual behaviour, blaming, 
marginalisation, male hegemony, power imbalance and fatalism.  Hence, they pointed out, to 
address HIV you need to address these other ‘vulnerabilities’, echoing Kalichman,  who warns, 
‘the barriers to prevention that we encountered for years are still with us, including stigma, 
addiction, poverty, apathy, denial and avoidance’(4).  Earlier on in the HIV epidemic, before 
HIV treatment was developed and widely available, there was more effort globally and within 
both these countries aimed at transforming structures and engendering ‘behaviour change’ with a 
combination of both community action and state involvement (20, 29, 34, 35).  Despite the 
genuine gains of these efforts – for example, patient empowerment, the HBC movement flagged 
by Zambian participants – there were limitations in the scale and the reach of the approaches 
(35), leaving ‘a vacuum for prevention interventions’ (4).  Part of the attraction and relief of new 
prevention bio-technologies is that the complexities of social realities – so inescapable for 
participants in these 21 places – can be boxed as ‘non-amenable’ to HIV advances, with answers 
for eventual ‘elimination’ of HIV lying rather in pills, gels, rubber protection and surgical 
procedures measured by models and statistics.  Yet, biomedical interventions are unlikely to live 
up to their promise if social determinants of access to prevention and treatment are not addressed 
(3). As one South African key informant expressed it, we should avoid, “one dimensional ways 
of trying to put easy solutions on something which is just much more complicated… And if we 
just look on the surface we are not going to address the underlying things about people’s 
relationships with one another”.  Therefore one clear risk of the primary focus of prevention 
narrowing to TasP is that social movements regress, including patient rights and provider ethics 
26 
 
(36).  The danger is that ‘equitable and universal’ commitment in practice (21) and in discourse 
is narrowed to the mere provision of prevention technologies and to a focus on ‘core transmitters’ 
(language used by mathematical modellers to refer to ‘at risk’ groups or ‘key populations’).   
 
Good Health versus Moral Responsibility – the risk of a slippage from public to individual 
responsibility? 
Participants in Zambia and South Africa were, in 2013, largely unfamiliar with the concept of 
treatment as prevention.  They were, however, living with ART as an option for managing HIV 
and had got wind of a renewed emphasis on prevention with the introduction of VMMC.  They 
were concerned about an accompanying de-emphasis on sexual behaviour change.  There was 
also a distant awareness of advances in curing HIV.  Treatment and prevention seemed, at first 
glance, to be experienced separately – with an obvious exception of PMTCT.  ‘Prevention’ 
seldom came into discussions about ‘ARVs’ and other forms of treatment and likewise ART did 
not habitually come into the prevention frame.  This was partly because this science had not yet 
been explained to many of them and they didn’t yet know about it.  It was also because it was not 
an easy ‘fit’, with the exception of PMTCT where the individual treatment of pregnant women 
living with HIV secured the collective well-being of society through ‘HIV-free children’.  The 
information about HIV treatment reducing HIV transmission could build on this familiarity with 
and support for PMTCT and on the wider understanding of HIV transmission and the 
effectiveness of ART.  
 
This analysis reveals two behavioural threads that connect treatment and prevention – ‘taking 
care of yourself’ and moral responsibility.  Without TasP being familiar, participants reiterated 
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that HIV prevention was about ‘taking care of yourself’ and, by extension, PLHIV taking care of 
themselves to maintain their health. This meant taking ART but also boosting their immune 
system and protecting themselves and others by using condoms.  This ‘taking care’ is 
engendered by years of caring for PLHIV, both before and since ART.   
 
However, alongside care, stigma can also sit (37) with the long time-scale of the HIV epidemic 
allowing participants to revert to ‘blaming the victims’ (3) despite scientific knowledge (20). 
Scattered throughout their discussions on HIV treatment and HIV prevention were moral 
overtones about appropriate and proper behaviour and the risk of transgression.  In South Africa, 
perhaps partly due to a stronger legacy of individual rights and presence of a quasi-welfare state, 
responsibility lay more heavily with ‘the system’ whereas in Zambia, responsibility lay more 
heavily in moral conduct of individuals.  In a recent paper Vernooij and colleagues examine a 
spread of responsibility underlying TasP uptake in Swaziland across national and individual 
levels (7).  In both Zambia and South Africa, but especially Zambia, this prescription for the 
‘adoption of moral responsible life’ (38) had strong Christian backing but had also been at the 
fore of earlier HIV interventions prior to ART being available.  When introducing the concept of 
treatment as prevention there was a tendency for participants to blame PLHIV for spreading ‘the 
virus, making them responsible, in turn, for containing ‘the virus’.  Field notes from one 
Zambian community record ‘commando’ as a nick-name for PLHIV who are on ART, 
explaining community perceptions that ‘Most of them [PLHIV] know they are HIV-positive but 
want to infect any other person they come across.  Hence the term ‘commando’ because it 
implies that when they infect others they are killing them just as commandos who shoot and kill 
people.  People… felt ART is contributing to the rise of HIV prevalence in the community 
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because it is helping PLHIV to disguise their sickness hence infecting others’ (Fieldnotes, 14th 
February 2013). Evidence for TasP programmes framing PLHIV as ‘infected vessels’ and ‘a 
means of prevention as opposed to people whose individual health matters’ (39) has been 
documented amongst adolescents living with HIV in Baltimore (ibid) and homosexuals in 
Australia(23).  This ‘responsibilising effect’ (40) raises ‘profound questions about the role of 
PLHIV in prevention of the transmission of HIV infection’ (ibid, 71). Philbin et al. argue ‘viral 
loads have come to represent the link between individual health and the public’s health’ (39). As 
a result of this link, ‘individuals have become subject to new models of HIV prevention and are 
made responsible in an unprecedented way’ (39).    Drawing on a qualitative study in Scotland, 
Young and colleagues (9) argue that TasP could increase the burden of prevention experienced 
by PLHIV (p.273).   Kippax warns that a reframing of ‘responsibilization’  which could occur 
alongside ‘treatment as prevention’ is likely to be ‘counterproductive’ (Kippax  personal 
communication). Vernooij and colleagues (7) further demonstrate that the acceptability of TasP 
can be improved by ‘understanding locally framed responsibilities’ (p. 12), drawing on the 
reframing of TasP away from public benefits of reducing transmission to the benefits of early 
treatment for all and individuals taking responsibility for their own health.   
 
We should, however, avoid ‘historical amnesia’ (20).  Scientific and global HIV transitions 
across the thirty years of the epidemic play a part in re-shaping responsibility for HIV and HIV-
related stigma. This is not lost on participants in this research.  One South African key informant 
describes, “If it’s [HIV] treated as a chronic disease.  I mean, we should have done that in the 80s 
then we wouldn’t have been here now.  Everything is hush, hush. If they just said it’s a viral 
infection, there’s no cure at the moment, but then they made the disease so ugly.  So 
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people…can’t move away from that. Those powers that be, they stigmatised the disease. Now we 
must sit with the brunt of that”.  Listening more carefully to participants suggests that we should 
be wary of TasP providing new opportunities for stigma and discrimination (40) and falling back 
into the ‘us’ and ‘them’ scenario that anti-stigma and human rights initiatives have tried so hard 
to break down.  Neither on the global stage, nor in all 21 study communities, was there much 
current evidence of substantial stigma reduction efforts.  Yet as Nguyen and colleagues 
comment, ‘it is time to move forwards, not backwards’ (3) and to actively reduce stigma and 
discrimination in order for TasP to be safely implemented (41).  The 2016 IAS Conference 
reiterated this point, reviving a stigma and discrimination focus as critical to future endeavours. 
Given the danger of responsibility sitting too heavily on the shoulders of PLHIV, TasP 
programmes could adopt an approach that advocates coupling the good news that early treatment 
protects health alongside broader motivations that build on the understanding of PMTCT and 
shared social action to prevent HIV.  
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